drugset / Trial / NCT07232732

A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity

NCT07232732

Phase 1 Active not recruiting 120 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.

Timeline

Start
2025-10-27
Primary completion
2026-07
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3549492 Unknown Oral

Indications